At the ASCO 2019 annual meeting, trial investigator, Kazuhiko Nakagawa discusses RELAY: A multinational, double-blind, randomized Phase III study of erlotinib in combination with ramucirumab or placebo in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NCT02411448).
1. What is the rationale for the use of ramucirumab plus erlotinib in metastatic EGFR-mutated non-small cell lung cancer (NSCLC)? (0:03)
2. Could you tell us a little about the RELAY study and its findings? (0:48)
3. What was the safety profile of ramucirumab plus erlotinib? (1:43)
4. Which patients are most likely to respond to this therapy? (2:49)
5. Following the success of the RELAY and REVEL studies, what will be the next steps in the clinical development of ramucirumab in NSCLC? (3:55)
Speaker disclosure: Kazuhiko Nakagawa has acted as a consultant for AstraZeneca, Eli Lilly, Boehringer Ingelheim and Roche.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Lung Cancer
Paula Ugalde, WCLC 2021: Screening, Incidental Nodules, and Adjuvant Therapy for Early-Stage Lung Cancer
touchONCOLOGY joins Dr Paula Ugalde (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) at WCLC 2021 to discuss her presentation on screening, incidental nodules and adjuvant therapy for early-stage lung cancer. Questions 1. Early detection of lung cancer improves disease outcomes – when and in which patients do you perform screening? (00:15-00:46) 2. […]
Antoinette Wozniak, WCLC 2021: Important Recent Developments in the Diagnosis and Management of Small Cell Lung Cancer
touchONCOLOGY joins Prof Antoinette Wozniak (UPMC Hillman Cancer Center, Pittsburgh, PA, USA) at WCLC 2021 to discuss the challenges of treating small cell lung cancer and the most important recent advances. Questions 1. Please can you outline the current prognosis for patients with small cell lung cancer (SCLC)? (00:26-02:37) 2. In your opinion, what are […]
Antoinette Wozniak, WCLC 2021: Highlights of the digital 2021 conference
touchONCOLOGY joins Editorial Board Member Prof Antoinette Wozniak (UPMC Hillman Cancer Center, Pittsburgh, PA, USA) at WCLC 2021 to discuss her highlights of the conference this year. Question What have been your particular highlights of the World Conference on Lung Cancer 2021? Disclosures: Antoinette Wozniak has no financial or non-financial conflicts of interest to declare […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!